Karyopharm Therapeutics Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $154.0K | $250.0K | $229.0K | $387.0K | $634.0K | $152.0K |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $107.3M | $86.9M | $97.7M | $60.1M | $28.5M | $14.1M | $8.6M |
| SG&A Expense | $24.9M | $23.9M | $21.6M | $15.9M | $5.9M | $2.4M | $1.8M |
| Operating Income | $-130.5M | $-110.7M | $-119.1M | $-75.8M | $-34.0M | $-15.9M | $-10.3M |
| Operating Margin | -8,133.2% | -71,903.9% | -47,630.4% | -33,120.5% | -8,772.6% | -2,506.3% | -6,783.6% |
| Interest Expense | — | — | — | $1.0K | — | — | — |
| Pretax Income | $-128.9M | $-109.4M | $-118.2M | $-75.8M | — | — | — |
| Income Tax Expense | $63.0K | $139.0K | $-118.1M | $-75.8M | $-33.9M | $-15.9M | — |
| Net Income | $-129.0M | $-109.6M | $-118.2M | $-75.8M | $-33.9M | $-15.9M | $-10.3M |
| Net Margin | -8,036.4% | -71,153.9% | -47,272.4% | -33,090.4% | -8,771.8% | -2,506.0% | -6,783.6% |
| EPS (Basic) | $-2.81 | $-2.92 | $-3.32 | $-2.43 | $-5.59 | $-8.95 | $-10.27 |
| EPS (Diluted) | $-2.81 | $-2.92 | $-3.32 | $-2.43 | $-5.59 | $-8.95 | $-10.27 |
| Shares Outstanding (Basic) | 49.5M | 41.9M | 35.9M | 32.7M | 29.6M | 2.1M | — |
| Shares Outstanding (Diluted) | 49.5M | 41.9M | 35.9M | 32.7M | 29.6M | 2.1M | — |
| Dividends Per Share | — | — | — | — | — | — | — |